Share Price and Basic Stock Data
Last Updated: December 6, 2025, 8:37 pm
| PEG Ratio | 1.89 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Caplin Point Laboratories Ltd has carved a niche in the pharmaceutical industry, with a market capitalization of ₹14,982 Cr. The company reported a steady revenue growth trajectory, with sales rising from ₹1,269 Cr in FY 2022 to ₹1,937 Cr in FY 2025, reflecting a compound annual growth rate that appears robust for the sector. The latest quarterly figures show sales of ₹410 Cr in September 2023, which is an increase from ₹395 Cr in June 2023. This consistent upward trend in revenues indicates not only effective market penetration but also a strong product portfolio that resonates well with customers. The company’s focus on generic and specialty pharmaceuticals seems to be paying off, as evidenced by their ability to sustain this growth amid a competitive landscape.
Profitability and Efficiency Metrics
Profitability metrics for Caplin Point are noteworthy, showcasing an operating profit margin (OPM) of 35%, which is commendable compared to industry averages. The net profit for the latest reported period stood at ₹567 Cr, demonstrating a healthy profit margin of nearly 27.92% for FY 2025. Additionally, the return on equity (ROE) of 22.7% and return on capital employed (ROCE) of 25.8% signal that the company is not only generating profits but is also efficiently utilizing its capital. The interest coverage ratio, an impressive 1218.62x, indicates that Caplin is well-positioned to service any potential debt, though it is worth noting the company has minimal borrowings at just ₹5 Cr. These metrics collectively illustrate a business model that is both profitable and efficient, providing a solid foundation for future growth.
Balance Sheet Strength and Financial Ratios
Caplin’s balance sheet reflects considerable strength, with total reserves reported at ₹3,144 Cr and negligible borrowings. This financial position suggests that the company is well-capitalized and has the capacity to invest in growth opportunities without the burden of significant debt. The current ratio of 6.97x also indicates a strong liquidity position, suggesting that Caplin can easily meet its short-term obligations. Moreover, the price-to-book value ratio of 5.48x, while relatively high, could be justified by the company’s strong growth prospects and profitability metrics. However, investors should be cautious, as high valuations can sometimes lead to volatility if growth expectations are not met. Overall, the balance sheet looks comfortable, positioning the company favorably in the eyes of potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Caplin Point Laboratories reveals a solid backing from its promoters, holding 70.57% of the company. This high promoter stake is generally a positive indicator, reflecting their confidence in the business’s long-term prospects. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold a combined 8.61%, which, while modest, has shown an upward trend, indicating growing interest. The number of shareholders has also seen fluctuations, with 93,753 registered shareholders as of the latest report. This suggests a stable base of retail investors, although the slight decline in public shareholding to 20.82% could raise some eyebrows. Nonetheless, the overall structure seems supportive, with institutional confidence likely contributing to price stability.
Outlook, Risks, and Final Insight
Looking ahead, Caplin Point Laboratories faces a landscape filled with both opportunities and challenges. The company’s strong revenue growth and profitability metrics provide a solid basis for future expansion, particularly as it navigates the complexities of the pharmaceutical sector. However, potential risks include market competition, regulatory hurdles, and the ever-present threat of pricing pressures in the generic drug market. Additionally, while the current high valuations may reflect confidence, they could also signal vulnerability to market corrections should growth falter. Investors might consider these dynamics when evaluating their positions. Overall, Caplin Point appears well-positioned but must continue to innovate and adapt to maintain its competitive edge in a rapidly evolving industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Caplin Point Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,112 Cr. | 377 | 479/192 | 85.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,580.44 Cr | 1,173.08 | 51.95 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 346 | 359 | 372 | 389 | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 |
| Expenses | 244 | 253 | 263 | 265 | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 |
| Operating Profit | 102 | 106 | 109 | 124 | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 |
| OPM % | 30% | 29% | 29% | 32% | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% |
| Other Income | 14 | 16 | 14 | 11 | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 11 | 11 | 11 | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 |
| Profit before tax | 105 | 110 | 112 | 124 | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 |
| Tax % | 18% | 17% | 13% | 18% | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% |
| Net Profit | 86 | 92 | 97 | 101 | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 |
| EPS in Rs | 11.21 | 12.09 | 12.84 | 13.45 | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 |
Last Updated: August 20, 2025, 12:25 pm
Below is a detailed analysis of the quarterly data for Caplin Point Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 510.00 Cr.. The value appears strong and on an upward trend. It has increased from 502.00 Cr. (Mar 2025) to 510.00 Cr., marking an increase of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 332.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 334.00 Cr. (Mar 2025) to 332.00 Cr., marking a decrease of 2.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 178.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2025) to 178.00 Cr., marking an increase of 10.00 Cr..
- For OPM %, as of Jun 2025, the value is 35.00%. The value appears strong and on an upward trend. It has increased from 33.00% (Mar 2025) to 35.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 184.00 Cr.. The value appears strong and on an upward trend. It has increased from 177.00 Cr. (Mar 2025) to 184.00 Cr., marking an increase of 7.00 Cr..
- For Tax %, as of Jun 2025, the value is 18.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00%.
- For Net Profit, as of Jun 2025, the value is 151.00 Cr.. The value appears strong and on an upward trend. It has increased from 145.00 Cr. (Mar 2025) to 151.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 20.10. The value appears strong and on an upward trend. It has increased from 18.76 (Mar 2025) to 20.10, marking an increase of 1.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:32 pm
| Metric | Jun 2014 | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 173 | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 1,989 |
| Expenses | 137 | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,291 | 1,316 |
| Operating Profit | 36 | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 647 | 673 |
| OPM % | 21% | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 33% | 34% |
| Other Income | 4 | 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 96 | 101 |
| Interest | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 66 |
| Profit before tax | 36 | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 707 |
| Tax % | 27% | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | |
| Net Profit | 26 | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 567 |
| EPS in Rs | 3.42 | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 74.35 |
| Dividend Payout % | 23% | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 51.04% | 22.07% | 21.47% | 16.74% | 22.71% | 22.40% | 22.28% | 17.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -28.97% | -0.60% | -4.72% | 5.96% | -0.31% | -0.12% | -4.93% |
Caplin Point Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 18% |
| 3 Years: | 15% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 20% |
| 3 Years: | 21% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 32% |
| 3 Years: | 40% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 24% |
| 3 Years: | 23% |
| Last Year: | 22% |
Last Updated: September 5, 2025, 1:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:05 am
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 47 | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,144 |
| Borrowings | 3 | 2 | 2 | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 5 |
| Other Liabilities | 115 | 134 | 137 | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 339 |
| Total Liabilities | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 3,504 |
| Fixed Assets | 102 | 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 555 |
| CWIP | 25 | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 177 |
| Investments | 0 | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 636 |
| Other Assets | 52 | 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,135 |
| Total Assets | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 3,504 |
Below is a detailed analysis of the balance sheet data for Caplin Point Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,144.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,619.00 Cr. (Mar 2025) to 3,144.00 Cr., marking an increase of 525.00 Cr..
- For Borrowings, as of Sep 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 222.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 217.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 339.00 Cr.. The value appears to be improving (decreasing). It has decreased from 352.00 Cr. (Mar 2025) to 339.00 Cr., marking a decrease of 13.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,208.00 Cr. (Mar 2025) to 3,504.00 Cr., marking an increase of 296.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 555.00 Cr.. The value appears strong and on an upward trend. It has increased from 546.00 Cr. (Mar 2025) to 555.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 144.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 33.00 Cr..
- For Investments, as of Sep 2025, the value is 636.00 Cr.. The value appears strong and on an upward trend. It has increased from 590.00 Cr. (Mar 2025) to 636.00 Cr., marking an increase of 46.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,928.00 Cr. (Mar 2025) to 2,135.00 Cr., marking an increase of 207.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,504.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,208.00 Cr. (Mar 2025) to 3,504.00 Cr., marking an increase of 296.00 Cr..
Notably, the Reserves (3,144.00 Cr.) exceed the Borrowings (5.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Jun 2014 | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 33.00 | 58.00 | 64.00 | 124.00 | 194.00 | 196.00 | 147.00 | 94.00 | 176.00 | 220.00 | 333.00 | 425.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 |
| Inventory Days | 35 | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 |
| Days Payable | 112 | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 106 | 103 |
| Cash Conversion Cycle | -77 | -67 | -99 | -81 | -16 | 61 | 251 | 166 | 138 | 173 | 194 | 175 |
| Working Capital Days | -181 | -128 | -114 | -29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 233 |
| ROCE % | 64% | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| UTI Aggressive Hybrid Fund | 243,164 | 0.63 | 38.28 | 243,164 | 2025-04-22 17:25:39 | 0% |
| UTI Large & Mid Cap Fund | 154,097 | 0.65 | 24.26 | 154,097 | 2025-04-22 17:25:39 | 0% |
| UTI Healthcare Fund | 120,000 | 1.74 | 18.89 | 120,000 | 2025-04-22 17:25:39 | 0% |
| UTI Retirement Fund | 107,327 | 0.36 | 16.89 | 107,327 | 2025-04-22 17:25:39 | 0% |
| ITI Pharma and Healthcare Fund | 14,758 | 1.27 | 2.32 | 14,758 | 2025-04-22 17:25:39 | 0% |
| Navi Aggressive Hybrid Fund | 3,600 | 0.51 | 0.57 | 3,600 | 2025-04-22 17:25:39 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 70.57 | 60.19 | 49.62 | 39.61 | 32.03 |
| Diluted EPS (Rs.) | 70.25 | 59.90 | 49.18 | 39.26 | 31.71 |
| Cash EPS (Rs.) | 79.88 | 67.79 | 55.60 | 46.88 | 38.13 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 365.25 | 299.18 | 241.46 | 189.35 | 159.08 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 365.25 | 299.18 | 241.46 | 189.35 | 159.08 |
| Revenue From Operations / Share (Rs.) | 254.93 | 223.05 | 193.25 | 167.47 | 140.30 |
| PBDIT / Share (Rs.) | 97.81 | 81.42 | 65.49 | 57.18 | 46.56 |
| PBIT / Share (Rs.) | 89.13 | 74.38 | 59.56 | 50.99 | 41.67 |
| PBT / Share (Rs.) | 89.05 | 74.32 | 59.47 | 50.90 | 41.46 |
| Net Profit / Share (Rs.) | 71.20 | 60.75 | 49.67 | 40.69 | 33.24 |
| NP After MI And SOA / Share (Rs.) | 70.57 | 60.18 | 49.57 | 39.56 | 32.03 |
| PBDIT Margin (%) | 38.36 | 36.50 | 33.88 | 34.14 | 33.18 |
| PBIT Margin (%) | 34.96 | 33.34 | 30.82 | 30.44 | 29.70 |
| PBT Margin (%) | 34.93 | 33.31 | 30.77 | 30.39 | 29.55 |
| Net Profit Margin (%) | 27.92 | 27.23 | 25.70 | 24.29 | 23.69 |
| NP After MI And SOA Margin (%) | 27.68 | 26.98 | 25.65 | 23.62 | 22.82 |
| Return on Networth / Equity (%) | 19.32 | 20.39 | 20.83 | 21.27 | 20.43 |
| Return on Capital Employeed (%) | 23.34 | 23.86 | 23.50 | 25.28 | 25.82 |
| Return On Assets (%) | 16.71 | 16.94 | 17.16 | 17.26 | 17.76 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 0.65 | 0.69 | 0.74 | 0.43 | 0.48 |
| Current Ratio (X) | 6.97 | 5.71 | 5.80 | 6.25 | 7.25 |
| Quick Ratio (X) | 5.88 | 4.62 | 4.72 | 5.15 | 6.00 |
| Inventory Turnover Ratio (X) | 5.54 | 0.73 | 0.80 | 1.41 | 0.85 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 7.47 | 8.05 | 0.00 | 1.24 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 6.69 | 7.19 | 0.00 | 1.08 |
| Earning Retention Ratio (%) | 0.00 | 92.53 | 91.95 | 0.00 | 98.76 |
| Cash Earning Retention Ratio (%) | 0.00 | 93.31 | 92.81 | 0.00 | 98.92 |
| Interest Coverage Ratio (X) | 1218.62 | 792.79 | 637.23 | 619.17 | 221.55 |
| Interest Coverage Ratio (Post Tax) (X) | 888.05 | 592.22 | 484.22 | 441.64 | 159.17 |
| Enterprise Value (Cr.) | 14664.80 | 9483.55 | 4065.67 | 4717.10 | 2632.14 |
| EV / Net Operating Revenue (X) | 7.57 | 5.60 | 2.77 | 3.72 | 2.48 |
| EV / EBITDA (X) | 19.73 | 15.34 | 8.18 | 10.88 | 7.47 |
| MarketCap / Net Operating Revenue (X) | 7.86 | 5.91 | 3.09 | 4.06 | 2.88 |
| Retention Ratios (%) | 0.00 | 92.52 | 91.94 | 0.00 | 98.75 |
| Price / BV (X) | 5.48 | 4.46 | 2.51 | 3.66 | 2.58 |
| Price / Net Operating Revenue (X) | 7.86 | 5.91 | 3.09 | 4.06 | 2.88 |
| EarningsYield | 0.03 | 0.04 | 0.08 | 0.05 | 0.07 |
After reviewing the key financial ratios for Caplin Point Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 70.57. This value is within the healthy range. It has increased from 60.19 (Mar 24) to 70.57, marking an increase of 10.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 70.25. This value is within the healthy range. It has increased from 59.90 (Mar 24) to 70.25, marking an increase of 10.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 79.88. This value is within the healthy range. It has increased from 67.79 (Mar 24) to 79.88, marking an increase of 12.09.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 365.25. It has increased from 299.18 (Mar 24) to 365.25, marking an increase of 66.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 365.25. It has increased from 299.18 (Mar 24) to 365.25, marking an increase of 66.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 254.93. It has increased from 223.05 (Mar 24) to 254.93, marking an increase of 31.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 97.81. This value is within the healthy range. It has increased from 81.42 (Mar 24) to 97.81, marking an increase of 16.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 89.13. This value is within the healthy range. It has increased from 74.38 (Mar 24) to 89.13, marking an increase of 14.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 89.05. This value is within the healthy range. It has increased from 74.32 (Mar 24) to 89.05, marking an increase of 14.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 71.20. This value is within the healthy range. It has increased from 60.75 (Mar 24) to 71.20, marking an increase of 10.45.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 70.57. This value is within the healthy range. It has increased from 60.18 (Mar 24) to 70.57, marking an increase of 10.39.
- For PBDIT Margin (%), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 36.50 (Mar 24) to 38.36, marking an increase of 1.86.
- For PBIT Margin (%), as of Mar 25, the value is 34.96. This value exceeds the healthy maximum of 20. It has increased from 33.34 (Mar 24) to 34.96, marking an increase of 1.62.
- For PBT Margin (%), as of Mar 25, the value is 34.93. This value is within the healthy range. It has increased from 33.31 (Mar 24) to 34.93, marking an increase of 1.62.
- For Net Profit Margin (%), as of Mar 25, the value is 27.92. This value exceeds the healthy maximum of 10. It has increased from 27.23 (Mar 24) to 27.92, marking an increase of 0.69.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 27.68. This value exceeds the healthy maximum of 20. It has increased from 26.98 (Mar 24) to 27.68, marking an increase of 0.70.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.32. This value is within the healthy range. It has decreased from 20.39 (Mar 24) to 19.32, marking a decrease of 1.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.34. This value is within the healthy range. It has decreased from 23.86 (Mar 24) to 23.34, marking a decrease of 0.52.
- For Return On Assets (%), as of Mar 25, the value is 16.71. This value is within the healthy range. It has decreased from 16.94 (Mar 24) to 16.71, marking a decrease of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.69 (Mar 24) to 0.65, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 6.97. This value exceeds the healthy maximum of 3. It has increased from 5.71 (Mar 24) to 6.97, marking an increase of 1.26.
- For Quick Ratio (X), as of Mar 25, the value is 5.88. This value exceeds the healthy maximum of 2. It has increased from 4.62 (Mar 24) to 5.88, marking an increase of 1.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.54. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 5.54, marking an increase of 4.81.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 7.47 (Mar 24) to 0.00, marking a decrease of 7.47.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.69 (Mar 24) to 0.00, marking a decrease of 6.69.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 92.53 (Mar 24) to 0.00, marking a decrease of 92.53.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.31 (Mar 24) to 0.00, marking a decrease of 93.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,218.62. This value is within the healthy range. It has increased from 792.79 (Mar 24) to 1,218.62, marking an increase of 425.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 888.05. This value is within the healthy range. It has increased from 592.22 (Mar 24) to 888.05, marking an increase of 295.83.
- For Enterprise Value (Cr.), as of Mar 25, the value is 14,664.80. It has increased from 9,483.55 (Mar 24) to 14,664.80, marking an increase of 5,181.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.57. This value exceeds the healthy maximum of 3. It has increased from 5.60 (Mar 24) to 7.57, marking an increase of 1.97.
- For EV / EBITDA (X), as of Mar 25, the value is 19.73. This value exceeds the healthy maximum of 15. It has increased from 15.34 (Mar 24) to 19.73, marking an increase of 4.39.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.86. This value exceeds the healthy maximum of 3. It has increased from 5.91 (Mar 24) to 7.86, marking an increase of 1.95.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 92.52 (Mar 24) to 0.00, marking a decrease of 92.52.
- For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.46 (Mar 24) to 5.48, marking an increase of 1.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.86. This value exceeds the healthy maximum of 3. It has increased from 5.91 (Mar 24) to 7.86, marking an increase of 1.95.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caplin Point Laboratories Ltd:
- Net Profit Margin: 27.92%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.34% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 888.05
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25.4 (Industry average Stock P/E: 51.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 27.92%
Fundamental Analysis of Caplin Point Laboratories Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3rd Floor, Ashvich Towers, Chennai (Madras) Tamil Nadu 600096 | investor@caplinpoint.net http://www.caplinpoint.net |
| Management | |
|---|---|
| Name | Position Held |
| Mr. C C Paarthipan | Chairman |
| Dr. Sridhar Ganesan | Managing Director |
| Dr. R Nagendran | Independent Director |
| Mr. S Deenadayalan | Independent Director |
| Mr. D Sathyanarayanan | Independent Director |
| Dr. C K Gariyali | Independent Director |
Caplin Point Laboratories Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹1,291.55 |
| Previous Day | ₹1,314.80 |
FAQ
What is the intrinsic value of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd's intrinsic value (as of 06 December 2025) is 1924.81 which is 1.95% lower the current market price of 1,963.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 14,924 Cr. market cap, FY2025-2026 high/low of 2,641/1,551, reserves of ₹3,144 Cr, and liabilities of 3,504 Cr.
What is the Market Cap of Caplin Point Laboratories Ltd?
The Market Cap of Caplin Point Laboratories Ltd is 14,924 Cr..
What is the current Stock Price of Caplin Point Laboratories Ltd as on 06 December 2025?
The current stock price of Caplin Point Laboratories Ltd as on 06 December 2025 is 1,963.
What is the High / Low of Caplin Point Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Caplin Point Laboratories Ltd stocks is 2,641/1,551.
What is the Stock P/E of Caplin Point Laboratories Ltd?
The Stock P/E of Caplin Point Laboratories Ltd is 25.4.
What is the Book Value of Caplin Point Laboratories Ltd?
The Book Value of Caplin Point Laboratories Ltd is 416.
What is the Dividend Yield of Caplin Point Laboratories Ltd?
The Dividend Yield of Caplin Point Laboratories Ltd is 0.31 %.
What is the ROCE of Caplin Point Laboratories Ltd?
The ROCE of Caplin Point Laboratories Ltd is 25.8 %.
What is the ROE of Caplin Point Laboratories Ltd?
The ROE of Caplin Point Laboratories Ltd is 22.7 %.
What is the Face Value of Caplin Point Laboratories Ltd?
The Face Value of Caplin Point Laboratories Ltd is 2.00.